For the Inventor, By the Inventor

Enter assignee name

Wilmington, DE, United States of America

Prelude Therapeutics Incorporated

USPTO Granted Patents = 18

% Expired Patents = 11.1

EPO Patents = 4

Trademarks = 2

Forward Citations = 12

Loading Chart...

Loading Chart...

28 inventors (with patents filed for the assignee):

Juan Luengo (11 out of 15 patents)

Hong Lin (11 out of 15 patents)

Michael Hawkins (9 out of 30 patents)

4. Rupa S Shetty (9 out of 11 patents)

5. Andrew Paul Combs (7 out of 128 patents)

6. Philip Michael Pitis (6 out of 56 patents)

7. Gisela Saborit Villarroya (5 out of 5 patents)

8. Jincong Zhuo (3 out of 76 patents)

9. Liang Lu (3 out of 33 patents)

10. Raul A Leal (3 out of 3 patents)

11. Xiaowei Wu (3 out of 3 patents)

12. Rupa Shetty (3 out of 4 patents)

13. Andrew W Buesking (2 out of 23 patents)

14. Sarah Pawley (2 out of 2 patents)

15. Ryan Holmes (2 out of 2 patents)

18 patents: Sort by Forward Citations

1. 12459950 - Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) (2025-11-04),

2. 12448389 - BRM targeting compounds and associated methods of use (2025-10-21),

3. 12440506 - Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) (2025-10-14),

4. 12414953 - Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) (2025-09-16),

5. 12129262 - CDK inhibitors and their use as pharmaceuticals (2024-10-29),

6. 11939340 - CDK inhibitors and their use as pharmaceuticals (2024-03-26),

7. 11702423 - BRM targeting compounds and associated methods of use (2023-07-18),

8. 11685744 - CDK inhibitors and their use as pharmaceuticals (2023-06-27),

9. 11673893 - CDK inhibitors and their use as pharmaceuticals (2023-06-13),

10. 11524962 - Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5) (2022-12-13),

11. 11254683 - Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) (2022-02-22),

12. 11220524 - Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) (2022-01-11),

13. 11214574 - Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) (2022-01-04),

14. 11208416 - Selective inhibitors of protein arginine methytransterase 5 (PRMT5) (2021-12-28),

15. 11130769 - Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein (2021-09-28),

Company Overview

Prelude Therapeutics Incorporated is a biotechnology company based in Wilmington, Delaware, focused on developing innovative therapies for cancer treatment. The organization specializes in precision medicine, utilizing a deep understanding of cancer biology to design targeted therapies that address specific genetic and molecular profiles of tumors. Prelude's research emphasizes the discovery and development of small molecule drugs aimed at improving patient outcomes in oncology, leveraging advanced drug design and development techniques.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

18 Patents

#227 in Wilmington, DE

#287 in Delaware

#17,952 in US

#34,187 in the World

Wilmington, DE, United States of America

Prelude Therapeutics Incorporated

Forward Citations = 12

28 inventors:

Juan Luengo (11 out of 15 patents)

Hong Lin (11 out of 15 patents)

Michael Hawkins (9 out of 30 patents)

4. Rupa S Shetty (9 out of 11 patents)

5. Andrew Paul Combs (7 out of 128 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Prelude Therapeutics Incorporated. Retrieved from https://idiyas.com/company/prelude-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…